Skip to main content
    P

    Pyxis Oncology Inc (PYXS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.41
    -0.17 (-10.76%)

    Market Cap: $188.98M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Pyxis Oncology Inc (PYXS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Pyxis Oncology reported revenue of $13.86M for the fiscal year ended Dec 31, 2025, down 14.2% from the year before. That year, net income was -$79.62M with a net margin of -574.5%, operating cash flow was -$63.50M and free cash flow was -$63.51M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$19.98M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$13.86M-14.2%82.8%-609.2%-574.5%
    Dec 2024$16.15M+809.1%97.1%-554.1%-478.9%
    Dec 2023$1.78MN/A100.0%-4628.2%-4154.8%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$13.86M$16.15M$1.78M$0$0$0$0
    Cost of revenue$2.39M$475.00K$0$0$0$0N/A
    Gross profit$11.47M$15.67M$1.78M$0$0$0N/A
    Research and development$73.70M$58.75M$49.59M$86.13M$51.05M$9.05M$1.22M
    Operating income-$84.42M-$89.46M-$82.20M-$123.48M-$69.72M-$12.89M-$2.88M
    Net income-$79.62M-$77.33M-$73.79M-$120.72M-$75.97M-$12.83M-$2.67M
    EBITDA-$80.29MN/AN/A-$123.48MN/A-$12.43M-$2.77M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$389.00K$631.00K$9.15M$684.00K$2.82M$515.00K-$2.21M$705.00K$708.00K$16.95M$576.00K
    Gross profit$0$389.00K$631.00K$6.77M$684.00K$2.82M$515.00K-$2.21M$705.00K$708.00K$16.47M$576.00K
    Operating income-$20.52M-$25.99M-$24.36M-$18.30M-$23.46M-$19.75M-$22.91M-$40.07M-$23.75M-$20.03M-$5.61M-$17.77M
    Net income-$19.98M-$25.35M-$23.27M-$18.11M-$22.00M-$18.35M-$21.16M-$35.57M-$21.20M-$17.30M-$3.26M-$15.60M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.69M by $13.73M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$91.52M$157.18M$173.73M$211.38M$280.02M$10.15M$19.81M
    Current assets$72.11M$132.44M$124.60M$186.61M$278.67M$8.10M$19.70M
    Cash and equivalents$15.42M$19.47M$9.66M$179.29M$274.74M$8.08M$19.69M
    Total liabilities$38.11M$36.43M$48.02M$50.55M$18.71M$3.85M$22.68M
    Short-term debt$1.69M$1.45M$1.23MN/A$165.00K$615.00K$9.00K
    Shareholder equity$53.41M$120.75M$125.70M$160.82M$261.31M-$15.64M-$2.87M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$76.77M$54.92M$64.30M$91.52M$105.60M$123.22M$135.87M$157.18M$195.31M$208.39M$220.22M$173.73M
    Total liabilities$35.45M$43.48M$33.03M$38.11M$36.83M$35.57M$32.76M$36.43M$41.63M$38.59M$36.06M$48.02M
    Cash and equivalents$3.86M$18.86M$5.77M$15.42M$8.92M$10.73M$12.76M$19.47M$12.06M$25.07M$27.97M$9.66M
    Shareholder equity$41.32M$11.44M$31.27M$53.41M$68.78M$87.64M$103.10M$120.75M$153.68M$169.79M$184.16M$125.70M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$63.50M-$57.67M-$70.71M-$89.33M-$35.33M-$10.08M-$2.24M
    Capital expenditures$9.00K$237.00K$6.73M$6.40M$540.00K$1.48M$1.48M
    Free cash flow-$63.51M-$57.91M-$77.44M-$95.73M-$35.87M-$11.57M-$3.72M
    Investing cash flow$58.86M$8.15M-$104.85M-$6.40M-$590.00K-$1.48M-$1.48M
    Financing cash flow$594.00K$59.33M$5.93M$183.00K$304.04M$35.00K$21.95M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$16.29M-$18.21M-$26.00M-$10.43M-$13.28M-$17.26M-$22.54M-$19.29M-$14.66M-$3.01M-$20.71M-$15.25M
    Capital expendituresN/AN/A$0$0$9.00K$0$0$0$0$0$237.00K$0
    Free cash flowN/AN/A-$26.00M-$10.43M-$13.29M-$17.26M-$22.54M-$19.29M-$14.66M-$3.01M-$20.95M-$15.25M
    Last 12 quarters

    Frequently Asked Questions About PYXS

    What is Pyxis Oncology's annual revenue?

    Pyxis Oncology reported revenue of $13.86M for the fiscal year ended Dec 31, 2025.

    How fast is Pyxis Oncology's revenue growing?

    Revenue was down 14.2% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Pyxis Oncology profitable?

    No. Pyxis Oncology reported net income of -$79.62M for the fiscal year ended Dec 31, 2025, with a net margin of -574.5%.

    How much free cash flow does PYXS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$63.50M minus capital expenditures of $9.00K produced free cash flow of -$63.51M.

    How much debt does Pyxis Oncology have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.69M and cash and equivalents of $15.42M.